Article Sidebar
Views PDF: 182
THE ROLE OF IMATINIB IN THE NEOADJUVANT TREATMENT OF GASTROINTESTINAL STROMAL TUMORS: 2 CASE REPORTS
Main Article Content
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract, approximately 1 to 3 percent of gastrointestinal cancer. The development of GISTs due to mutations in the KIT gene accounts for 78 to 88 percent, the most common sites are in the stomach (40 to 60 percent), small intestine (20 to 30 percent) and other sites. The diagnosis of GISTs is using histopathology and CD117 positive on immunohistochemistry (IHC), complete resection is the mainstay therapy, adjuvant imatinib therapy increases overall survival and decreases recurrence rate. For newly diagnosed GISTs in advanced stage, surgery cannot completely resect tumor, many complications, neo-adjuvant imatinib therapy reduce tumor size, downstaging, advantages for radical surgical and improve treatment outcomes. Two clinical cases illustrate successful neoadjuvant imatinib for patients with advanced stage GISTs at National cancer hospital.
Article Details
Keywords
Gastrointestinal stromal tumors, neo-adjuvant treatment, imatinib
References
2. Liang X., Yu H., Zhu L.-H., et al. (2013). Gastrointestinal stromal tumors of the duodenum: Surgical management and survival results. World J Gastroenterol WJG, 19(36), 6000–6010.
3. Patel S.R. and Reichardt P. (2021). An updated review of the treatment landscape for advanced gastrointestinal stromal tumors. Cancer, 127(13), 2187–2195.
4. Kurokawa Y., Yang H.-K., Cho H., et al. (2017). Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer, 117(1), 25–32.
5. Wang D., Zhang Q., Blanke C.D., et al. (2012). Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol, 19(4), 1074–1080.
6. Casali P.G., Jost L., Reichardt P., et al. (2009). Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol, 20 Suppl 4, 64–67.